CAC
CORT icon

Cowen and Company’s Corcept Therapeutics CORT Stock Holding History

Cowen and Company’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,935
Closed -$196K – 664
2021
Q3 		$196K Sell
9,935
-28,899
-74% -$605K 0.01% 264
2021
Q2 		$854K Buy
+38,834
New +$864K 0.04% 145

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cowen and Company's CORT Position: Q4 2021 in Review

Cowen and Company sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 9,935 shares — an estimated $196K sold.

Cowen and Company first reported a position in CORT in Q2 2021 and held it in 2 quarters. The position peaked at $854K in Q2 2021. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

  • Cowen and Company reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 9,935 Corcept Therapeutics shares in Q4 2021, an estimated $196K.
  • Cowen and Company first reported a position in Corcept Therapeutics in Q2 2021 and held it in 2 quarters.
  • Cowen and Company's Corcept Therapeutics position peaked at $854K in Q2 2021.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.